![]() | ||||||||
business | ||||||||
VIDEO | ||||||||
AstraZeneca Is Selling Its Antibiotics Business to Pfizer AstraZeneca has agreed to sell its small molecule antibiotics business to Pfizer in a deal that could reach more than $1.5 billion.
| ||||||||
Clock running out on Clinton Foundation probe? Former Whitewater Independent Counsel Robert Ray on the potential political fallout from the Clinton Foundation investigation.
| ||||||||
Millennials making excuses instead of a retirement plan? Personal development advisor Larry Winget on why Millennials and all Americans need to create a retirement plan ASAP.
| ||||||||
Swing state polls showing Clinton leading Trump Rasmussen Media Group President Scott Rasmussen breaks down the swing state polls suggesting Clinton leading Trump.
| ||||||||
How FreshGrade is changing the traditional classroom The co-founders of FreshGrade reveal how technology is blending your child's progress inside and outside of school.
| ||||||||
Markets done with 2016 gains? Michael Binger, Gradient Investments senior portfolio manager, discusses his expectations for Jackson Hole, and whether the markets have notched ...
| ||||||||
Sheriff Clarke on the black vote Milwaukee County Sheriff David Clarke on how Donald Trump can court black voters.
| ||||||||
McFarland on HRC: Zero success on foreign policy Fox News National Security Analyst KT McFarland questions the media coverage of Hillary Clinton's email scandal while she was Secretary of State.
| ||||||||
Obama details federal response for Louisiana flood victims During a visit to Louisiana to observe flood damage, President Barack Obama outlined the federal aid response to victims and their families.
| ||||||||
Is Hillary Clinton making a mistake delaying a visit to Louisiana flood zone? Former Sen. Mary Landrieu, (D-LA), on the aftermath of the flooding in Louisiana and the recovery efforts.
| ||||||||
See more results | Edit this alert |
You have received this email because you have subscribed to Google Alerts. |
![]() |
Send Feedback |
0 comments:
Post a Comment